Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

Jurrien Ten Berg; Dirk Sibbing; Bianca Rocca; Eric Van Belle; Bernard Chevalier; Jean-Philippe Collet; Dariusz Dudek; Martine Gilard; Diana A Gorog; Julia Grapsa; Erik Lerkevang Grove; Patrizio Lancellotti; Anna Sonia Petronio; Andrea Rubboli; Lucia Torracca; Gemma Vilahur; Adam Witkowski; Julinda Mehilli

doi:10.1093/eurheartj/ehab196

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

Jurrien Ten Berg, Dirk Sibbing, Bianca Rocca, Eric Van Belle, Bernard Chevalier, Jean-Philippe Collet, Dariusz Dudek, Martine Gilard, Diana A Gorog, Julia Grapsa, Erik Lerkevang Grove, Patrizio Lancellotti, Anna Sonia Petronio, Andrea Rubboli, Lucia Torracca, Gemma Vilahur, Adam Witkowski, Julinda Mehilli

Research output: Contribution to journal › Article

Abstract

Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.

Original language	English
Pages (from-to)	N/A-N/A
Journal	European Heart Journal
DOIs	https://doi.org/10.1093/eurheartj/ehab196
Publication status	Published - 2021

Keywords

Antithrombotic treatment
Transcatheter aortic valve implantation

Access to Document

10.1093/eurheartj/ehab196

Fingerprint

Dive into the research topics of 'Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease'. Together they form a unique fingerprint.

Cite this

Ten Berg, J., Sibbing, D., Rocca, B., Van Belle, E., Chevalier, B., Collet, J.-P., Dudek, D., Gilard, M., Gorog, D. A., Grapsa, J., Grove, E. L., Lancellotti, P., Petronio, A. S., Rubboli, A., Torracca, L., Vilahur, G., Witkowski, A., & Mehilli, J. (2021). Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal, N/A-N/A. https://doi.org/10.1093/eurheartj/ehab196

Ten Berg, Jurrien ; Sibbing, Dirk ; Rocca, Bianca et al. / Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. In: European Heart Journal. 2021 ; pp. N/A-N/A.

@article{750efc26833b4b5abefebcc89c7e3aaf,

title = "Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease",

abstract = "Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.",

keywords = "Antithrombotic treatment, Transcatheter aortic valve implantation, Antithrombotic treatment, Transcatheter aortic valve implantation",

author = "{Ten Berg}, Jurrien and Dirk Sibbing and Bianca Rocca and {Van Belle}, Eric and Bernard Chevalier and Jean-Philippe Collet and Dariusz Dudek and Martine Gilard and Gorog, {Diana A} and Julia Grapsa and Grove, {Erik Lerkevang} and Patrizio Lancellotti and Petronio, {Anna Sonia} and Andrea Rubboli and Lucia Torracca and Gemma Vilahur and Adam Witkowski and Julinda Mehilli",

year = "2021",

doi = "10.1093/eurheartj/ehab196",

language = "English",

pages = "N/A--N/A",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford : Oxford University Press United Kingdom: Harcourt Publishers Limitedinternational.com, Fax: 011 44 20 83085876",

}

Ten Berg, J, Sibbing, D, Rocca, B, Van Belle, E, Chevalier, B, Collet, J-P, Dudek, D, Gilard, M, Gorog, DA, Grapsa, J, Grove, EL, Lancellotti, P, Petronio, AS, Rubboli, A, Torracca, L, Vilahur, G, Witkowski, A & Mehilli, J 2021, 'Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease', European Heart Journal, pp. N/A-N/A. https://doi.org/10.1093/eurheartj/ehab196

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. / Ten Berg, Jurrien; Sibbing, Dirk; Rocca, Bianca et al.
In: European Heart Journal, 2021, p. N/A-N/A.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

AU - Ten Berg, Jurrien

AU - Sibbing, Dirk

AU - Rocca, Bianca

AU - Van Belle, Eric

AU - Chevalier, Bernard

AU - Collet, Jean-Philippe

AU - Dudek, Dariusz

AU - Gilard, Martine

AU - Gorog, Diana A

AU - Grapsa, Julia

AU - Grove, Erik Lerkevang

AU - Lancellotti, Patrizio

AU - Petronio, Anna Sonia

AU - Rubboli, Andrea

AU - Torracca, Lucia

AU - Vilahur, Gemma

AU - Witkowski, Adam

AU - Mehilli, Julinda

PY - 2021

Y1 - 2021

N2 - Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.

AB - Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.

KW - Antithrombotic treatment

KW - Transcatheter aortic valve implantation

KW - Antithrombotic treatment

KW - Transcatheter aortic valve implantation

UR - http://hdl.handle.net/10807/174399

U2 - 10.1093/eurheartj/ehab196

DO - 10.1093/eurheartj/ehab196

M3 - Article

SN - 0195-668X

SP - N/A-N/A

JO - European Heart Journal

JF - European Heart Journal

ER -

Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal. 2021;N/A-N/A. doi: 10.1093/eurheartj/ehab196

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this